ABSTRACT
Background Mood disorders, including major depression (MD) and bipolar disorder (BD), are risk factors for Alzheimer’s disease (AD) and possibly share an overlapping genetic architecture. However, few studies have investigated the shared loci and potential pleiotropy among these disorders.
Methods We carried out a systematic analytical pipeline using GWAS data and three complementary (genome-wide, single variant, and gene-level) statistical approaches to investigate the genetic overlap among MD, BD, and AD.
Results GWAS summary statistics data from 679,973 individuals were analyzed herein (59,851 MD cases and 113,154 controls; 20,352 BD cases and 31,358 controls; and 71,880 AD cases and 383,378 controls). We identified a significant positive genetic correlation between MD and AD (rG = 0.162; s.e. = 0.064; p = 0.012), and between BD and AD (rG = 0.162; s.e. = 0.068; p = 0.018). We also identified two pleiotropic candidate genes for MD and AD (TMEM106B and THSD7A) and three forBD and AD (MTSS2, VAC14, and FAF1), and reported candidate biological pathways associated with all three disorders.
Discussion Our study identified genetic loci and mechanisms shared by mood disorders and AD. These findings could be relevant to better understand the higher risk for AD among individuals with mood disorders, and to propose new interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by 'CAMH's internal funding mechanisms. Dr. Diniz is supported by NIH grants R01MH115953 and R01MH118311.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary statistics used in the present study were publicly available online in the following links: Alzheimer's disease: Jansen et al. (2019) - https://ctg.cncr.nl/software/summary_statistics; Bipolar disorder: Stahl et al., (2019) - https://www.med.unc.edu/pgc/download-results/; and Major depression: Wray et al., (2018) - https://www.med.unc.edu/pgc/download-results/.
